Buchumschlag

Diagnosis and Management of Waldenstrom's Macroglobulinemia

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Steven P. Treon, Shayna Sarosiek, Jorge J. Castillo
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Hematological Oncology
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Rapid and Sensitive Detection of the MYD88 L265P Mutation for Lymphoplasmocytic Lymphoma/Waldenström's Macroglobulinemia via CRISPR‐Cas12a
von: Rumei Sun, et al.
Veröffentlicht: (2025)

Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications
von: Alberto Guijosa, et al.
Veröffentlicht: (2026)

Depth of Response From Fixed‐Duration Treatment Is Associated With Superior Survival in Waldenstrom Macroglobulinemia
von: Jonas Paludo, et al.
Veröffentlicht: (2025)

Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
von: Jorge J. Castillo, et al.
Veröffentlicht: (2026)

147 | UPDATED EFFICACY & SAFETY OF BTK DEGRADER BGB‐16673 IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA (R/R WM): ONGOING PHASE 1 CaDAnCe‐101 RESULTS
von: A. M. Frustaci, et al.
Veröffentlicht: (2025)

887 | CYTOKINE STORM WARNING: DIFFERENTIATING LYMPHOMA‐ASSOCIATED HLH FROM LYMPHOID MALIGNANCY THROUGH INFLAMMATORY PROFILING
von: R. Prakash, et al.
Veröffentlicht: (2025)

In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T‐Cell Neoplasms
von: Marie Therese Manipadam, et al.
Veröffentlicht: (2024)

Advances in the Management of Relapsed/Refractory CLL and Richter Transformation
von: Nathalie Javidi‐Sharifi, et al.
Veröffentlicht: (2025)

Managing Myelofibrosis: Matching Advances in Treatments With Clinical Unmet Needs
von: Tze Wei Chan, et al.
Veröffentlicht: (2025)

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
von: Giacomo Loseto, et al.
Veröffentlicht: (2025)

Re: Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience
von: Theodoros P. Vassilakopoulos, et al.
Veröffentlicht: (2025)

Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real‐World Study
von: Ben Varon, et al.
Veröffentlicht: (2026)

Treatment‐related toxicity disparities in adult Hispanic acute lymphoblastic leukemia patients receiving pegaspargase‐based regimens: A multicenter electronic health research network study
von: Benjamin J. Lee, et al.
Veröffentlicht: (2024)

International Cost‐Effectiveness Analysis of Nivolumab Versus Brentuximab Vedotin for Patients With Advanced‐Stage Classic Hodgkin's Lymphoma
von: Youwen Zhu, et al.
Veröffentlicht: (2026)

449 | BRIDGING TO CAR‐T CELL THERAPY IN LARGE B‐CELL LYMPHOMA WITH EITHER CONVENTIONAL THERAPY OR THE CD3xCD20 BISPECIFIC ANTIBODY GLOFITAMAB
von: J. K. Schleifenbaum, et al.
Veröffentlicht: (2025)

778 | THE IMPORTANCE OF INFLAMMATORY BIOMARKERS IN PREDICTING RESPONSE TO CAR‐T IN PATIENTS WITH LYMPHOMA
von: N. De Lucas Torres, et al.
Veröffentlicht: (2025)

Remote Monitoring of CAR T‐Cell Treated Patients by a Specialized Nurse to Detect and Manage Late Complications: Report of the CARAMA Program
von: Fanny Colin, et al.
Veröffentlicht: (2025)

780 | DEATHS IN PATIENTS IN COMPLETE REMISSION WITH CAR T THERAPY. TOXICITY INTO ACCOUNT?
von: S. Sequero Lopez, et al.
Veröffentlicht: (2025)

21 | PROGNOSTIC VALUE OF CIRCULATING TUMOR DNA IN PATIENTS WITH ADVANCED STAGE CLASSIC HODGKIN LYMPHOMA TREATED ON SWOG S1826
von: J. Paczkowska, et al.
Veröffentlicht: (2025)

Long‐Term Outcomes and Management Strategies With DA‐R‐EPOCH in Primary Mediastinal B‐Cell Lymphoma: Insights From a Single‐Center Experience
von: Robin Noel, et al.
Veröffentlicht: (2025)

ON06 | IDENTIFYING NURSING TRAINING NEEDS FOR THE MANAGEMENT OF BISPECIFIC DRUGS AND PATIENT FOLLOW‐UP IN ONCO‐HEMATOLOGY UNITS: A NON‐INTERVENTIONAL, E‐SURVEY BELL STUDY
von: M. Bou, et al.
Veröffentlicht: (2025)

494 | IMMUNOPROFILING OF THE TUMOR MICROENVIRONMENT IN DLBCL USING MULTIPLEXED IMMUNOFLUORESCENCE AND QuPath ANALYSIS
von: J. Hashemi, et al.
Veröffentlicht: (2025)

170 | ROLE OF NON‐CODING RNAs AND DNA METHYLATION IN REGULATING INTRACELLULAR SIGNALING AND CYTOKINE PATHWAYS IN MYD88WT WALDENSTRÖM MACROGLOBULINEMIA: A MULTI‐OMIC ANALYSIS
von: K. L. Chohan, et al.
Veröffentlicht: (2025)

138 | PHASE 2 ELARA TRIAL 4‐YEAR UPDATE: CLINICAL OUTCOMES OF TISAGENLECLEUCEL IN PATIENTS (PTS) WITH HIGH‐RISK RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (R/R FL)
von: C. Thieblemont, et al.
Veröffentlicht: (2025)

441 | GOLCADOMIDE, A CEREBLON E3 LIGASE MODULATOR (CELMoD) AGENT ± RITUXIMAB, IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA: UPDATED PHASE 1/2 RESULTS
von: R. Cordoba, et al.
Veröffentlicht: (2025)

635 | SYMPTOM BURDEN AND HEALTH‐RELATED QUALITY OF LIFE IN PATIENTS WITH AGGRESSIVE NON‐HODGKIN LYMPHOMA IN CHINA: A CROSS‐SECTIONAL STUDY
von: J. Jin, et al.
Veröffentlicht: (2025)

297 | CAUSES OF EXCESS NON‐LYMPHOMA DEATH IN 60,000 PATIENTS WITH DLBCL DIAGNOSED IN ENGLAND, 1997–2020: AN OBSERVATIONAL COHORT STUDY WITH UP TO 25 YEARS FOLLOW‐UP
von: A. Challenger, et al.
Veröffentlicht: (2025)

Managing Treatment‐Emergent Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CAR‐T Cell Therapy: A Case‐Based Review of the use of Emapalumab
von: Livia Donzelli, et al.
Veröffentlicht: (2025)

255 | THE EFFICACY, SAFETY AND RATIONALITY OF ORELABRUTINIB PLUS OBINUTUZUMAB (O2) IN SYSTEMIC TREATMENT‐NAÏVE MARGINAL ZONE LYMPHOMA: A PROSPECTIVE COHORT STUDY
von: J. Xu, et al.
Veröffentlicht: (2025)

72 | SEQUOIA 5‐YEAR FOLLOW‐UP IN ARM C: FRONTLINE ZANUBRUTINIB IN PATIENTS WITH DEL(17P) AND TREATMENT‐NAIVE CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL)
von: C. S. Tam, et al.
Veröffentlicht: (2025)

622 | P+R‐ICE: PEMBROLIZUMAB IN COMBINATION WITH R‐ICE CHEMOTHERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
von: L. Stanton, et al.
Veröffentlicht: (2025)

850 | GOLSEEK‐2: A PHASE 2 RANDOMIZED, OPEN‐LABEL STUDY OF GOLCADOMIDE IN COMBINATION WITH RITUXIMAB IN PARTICIPANTS WITH NEWLY DIAGNOSED ADVANCED‐STAGE FOLLICULAR LYMPHOMA
von: P. Luigi Zinzani, et al.
Veröffentlicht: (2025)

729 | EXPERIENCE WITH VECADD IN ADVANCED CLASSIC HODGKIN LYMPHOMA IN PREGNANT AND NON‐PREGNANT FEMALE PATIENTS
von: A. S. Robertz, et al.
Veröffentlicht: (2025)

604 | POLATUZUMAB VEDOTIN AS AN EFFECTIVE SALVAGE THERAPY FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA RESISTANTANCE TO BTK AND BCL INHIBITORS
von: P. Yang, et al.
Veröffentlicht: (2025)

450 | 5‐5‐5 ABRT (ADAPTIVE BRIDGING RADIATION THERAPY)—ARTIFICIAL INTELLIGENCE ENTERS THE CAR (‐T) IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA: UPDATED ANALYSIS
von: H. Ababneh, et al.
Veröffentlicht: (2025)

71 | FINAL ANALYSIS OF FIXED‐DURATION IBRUTINIB + VENETOCLAX FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)/SMALL LYMPHOCYTIC LYMPHOMA (SLL) IN THE PHASE 2 CAPTIVATE STUDY
von: P. Ghia, et al.
Veröffentlicht: (2025)

358 | PD‐1‐BASED SALVAGE THERAPY FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA: A MULTICENTER REAL‐WORLD ANALYSIS
von: H. Tharmaseelan, et al.
Veröffentlicht: (2025)

134 | EFFICACY AND SAFETY OF FIRST‐LINE IBRUTINIB PLUS VENETOCLAX IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO WERE OLDER OR HAD TP53 MUTATIONS IN THE SYMPATICO STUDY
von: M. Wang, et al.
Veröffentlicht: (2025)

62 | A PHASE II TRIAL OF PEMBROLIZUMAB CONCURRENT WITH RADIOTHERAPY FOR FRAIL PATIENTS WITH NEWLY DIAGNOSED EARLY‐STAGE NATURAL KILLER/T‐CELL LYMPHOMA (IELSG50)
von: H. Zhong, et al.
Veröffentlicht: (2025)

496 | PATIENTS WITH LYMPHOMA IN HIGH RISK OF TREATMENT‐RELATED DEATH CAN BE IDENTIFIED BY CHIP AND MOSAIC CHROMOSOMAL ALTERATIONS
von: M. A. Heldbo, et al.
Veröffentlicht: (2025)